{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:41:11Z","timestamp":1772066471582,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11845-013-1036-5","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T12:04:19Z","timestamp":1383566659000},"page":"449-453","source":"Crossref","is-referenced-by-count":48,"title":["Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction"],"prefix":"10.1007","volume":"183","author":[{"given":"U.","family":"Ozturk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yesil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. N. G.","family":"Goktug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gucuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tuygun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. C.","family":"Sener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Nalbant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Imamoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ucl.2007.08.017","volume":"34","author":"FL Taylor","year":"2007","unstructured":"Taylor FL, Levine LA (2007) Peyronie\u2019s disease. Urol Clin North Am 34:517\u2013534","journal-title":"Urol Clin North Am"},{"key":"1036_CR2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","volume":"169","author":"SS Gholami","year":"2003","unstructured":"Gholami SS, Gonzalez-Cadavid NF, Lin CS et al (2003) Peyronie\u2019s disease: a review. J Urol 169:1234\u20131241","journal-title":"J Urol"},{"key":"1036_CR3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","volume":"6","author":"A M\u00fcller","year":"2009","unstructured":"M\u00fcller A, Mulhall JP (2009) Peyronie\u2019s disease intervention trials: methodological challenges and issues. J Sex Med 6:848\u2013861","journal-title":"J Sex Med"},{"key":"1036_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1743-6109.2008.01104.x","volume":"6","author":"NF Gonzalez-Cadavid","year":"2009","unstructured":"Gonzalez-Cadavid NF, Rajfer J (2009) Experimental models of Peyronie\u2019s disease. Implications for new therapies. J Sex Med 6:303\u2013313","journal-title":"J Sex Med"},{"key":"1036_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","volume":"7","author":"NF Gonzalez-Cadavid","year":"2010","unstructured":"Gonzalez-Cadavid NF, Rajfer J (2010) Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an anti-fibrotic strategy. Nat Rev Urol 7:215\u2013221","journal-title":"Nat Rev Urol"},{"key":"1036_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319\u2013326","journal-title":"Int J Impot Res"},{"key":"1036_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1743-6109.2012.02825.x","volume":"10","author":"SC Sikka","year":"2013","unstructured":"Sikka SC, Hellstrom WJ, Brock G, Morales AM (2013) Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 10:120\u2013129","journal-title":"J Sex Med"},{"key":"1036_CR8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MOU.0b013e3283314a87","volume":"19","author":"R Kumar","year":"2009","unstructured":"Kumar R, Nehra A (2009) Surgical and minimally invasive treatments for Peyronie\u2019s disease. Curr Opin Urol 19:589\u2013594","journal-title":"Curr Opin Urol"},{"key":"1036_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.eururo.2006.02.059","volume":"49","author":"EW Hauck","year":"2009","unstructured":"Hauck EW, Diemer T, Schmelz HU et al (2009) A critical analysis of nonsurgical treatment of Peyronie\u2019s disease. Eur Urol 49:987\u2013997","journal-title":"Eur Urol"},{"key":"1036_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2164\/jandrol.108.006221","volume":"30","author":"WJ Hellstrom","year":"2009","unstructured":"Hellstrom WJ (2009) Medical management of Peyronie\u2019s disease. J Androl 30:397\u2013405","journal-title":"J Androl"},{"key":"1036_CR11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4321\/S0004-06142009000800002","volume":"62","author":"AJ Vanni","year":"2009","unstructured":"Vanni AJ, Bennett NE (2009) Current treatment and management of the acute phase of Peyronie\u2019s disease. Arch Esp Urol 62:614\u2013622","journal-title":"Arch Esp Urol"},{"issue":"1","key":"1036_CR12","first-page":"87","volume":"4","author":"T Erdogru","year":"2002","unstructured":"Erdogru T, Savas M, Yilmaz N et al (2002) Evaluation of penile hemodynamic status and adjustment of treatment alternatives in Peyronie\u2019s disease. Asian J Androl 4(1):87\u201390","journal-title":"Asian J Androl"},{"key":"1036_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)35997-9","volume":"149","author":"JA Lopez","year":"1993","unstructured":"Lopez JA, Jarow JP (1993) Penile vascular evaluation of men with Peyronie\u2019s disease. J Urol 149:53\u201355","journal-title":"J Urol"},{"key":"1036_CR14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0022-5347(05)01018-9","volume":"175","author":"S Deveci","year":"2006","unstructured":"Deveci S, Palese M, Parker M et al (2006) Erectile function profiles in men with Peyronie\u2019s disease. J Urol 175:1807\u20131811","journal-title":"J Urol"},{"key":"1036_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.ijir.3900569","volume":"12","author":"A Kadio\u011flu","year":"2000","unstructured":"Kadio\u011flu A, Tefekli A, Erol H et al (2000) Color Doppler ultrasound assessment of penile vascular system in men with Peyronie\u2019s disease. Int J Impot Res 12:263\u2013267","journal-title":"Int J Impot Res"},{"key":"1036_CR16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0022-5347(01)65370-9","volume":"157","author":"W Weidner","year":"1997","unstructured":"Weidner W, Schroeder-Printzen I, Weiske WH et al (1997) Sexual dysfunction in Peyronie\u2019s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 157:325\u2013328","journal-title":"J Urol"},{"key":"1036_CR17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/sj.ijir.3900912","volume":"14","author":"LA Levine","year":"2002","unstructured":"Levine LA, Latchamsetty KC (2002) Treatment of erectile dysfunction in patients with Peyronie\u2019s disease using sildenafil citrate. Int J Impot Res 14:478\u2013482","journal-title":"Int J Impot Res"},{"key":"1036_CR18","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka AI, Hassoba HM, Chui RM et al (1997) An animal model of Peyronie\u2019s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 158:2284\u20132290","journal-title":"J Urol"},{"key":"1036_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","volume":"6","author":"MG Ferrini","year":"2002","unstructured":"Ferrini MG, Vernet D, Magee TR et al (2002) Anti-fibrotic role of inducible nitric oxide synthase. Nitric Oxide 6:283\u2013294","journal-title":"Nitric Oxide"},{"key":"1036_CR20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/path.1427","volume":"200","author":"G Gabbiani","year":"2003","unstructured":"Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500\u2013503","journal-title":"J Pathol"},{"key":"1036_CR21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/jpet.108.137422","volume":"326","author":"T Nagayama","year":"2008","unstructured":"Nagayama T, Zhang M, Hsu S et al (2008) Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 326:380\u2013387","journal-title":"J Pharmacol Exp Ther"},{"key":"1036_CR22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pupt.2009.11.002","volume":"23","author":"A Yildirim","year":"2010","unstructured":"Yildirim A, Ersoy Y, Ercan F et al (2010) Phosphodiesterase-5 inhibition by sildenafil citrate in a rat model of bleomycin-induced lung fibrosis. Pulm Pharmacol Ther 23:215\u2013221","journal-title":"Pulm Pharmacol Ther"},{"issue":"262","key":"1036_CR23","first-page":"276","volume":"7","author":"D Vernet","year":"2002","unstructured":"Vernet D, Ferrini MG, Valente EGA et al (2002) Effect of nitric oxide on fibroblast differentiation in to myofibroblasts in cell cultures from the Peyronie\u2019s fibrotic plaque and in its rat model in vivo. Nitric Oxide 7(262):276","journal-title":"Nitric Oxide"},{"key":"1036_CR24","first-page":"51","volume":"3","author":"NF Gonzalez-Cadavid","year":"1999","unstructured":"Gonzalez-Cadavid NF, Ignarro L, Rajfer J (1999) Nitric oxide and cyclic GMP in the penis. Mol Urol 3:51\u201359","journal-title":"Mol Urol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-013-1036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-013-1036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-013-1036-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T23:54:58Z","timestamp":1564617298000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-013-1036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1007\/s11845-013-1036-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]}}}